Oestrogens and the lower urinary tract
|
|
- Liliana Hodges
- 5 years ago
- Views:
Transcription
1 BJOG: an International Journal of Obstetrics and Gynaecology December 2004, Vol. 111, Supplement 1, pp Oestrogens and the lower urinary tract Dudley Robinson, Linda Cardozo INTRODUCTION The female genital and lower urinary tracts share a common embryological origin, arising from the urogenital sinus. Both are sensitive to the effects of female sex steroid hormones. Oestrogen is known to have an important role in the function of the lower urinary tract throughout adult life with oestrogen and progesterone receptors demonstrated in the vagina, urethra, bladder and pelvic floor musculature. 1,2 This is supported by the fact that oestrogen deficiency occurring following the menopause is known to cause atrophic changes within the urogenital tract, 3 and is associated with urinary symptoms such as frequency, urgency, nocturia, incontinence, recurrent infection. These may also coexist with symptoms of vaginal atrophy such as dyspareunia, itching, burning and dryness. Epidemiological studies have implicated oestrogen deficiency in the aetiology of lower urinary tract symptoms with 70% of women relating the onset of urinary incontinence to their final menstrual period. 3 Lower urinary tract symptoms have been shown to be common in postmenopausal women attending a menopause clinic with 20% complaining of severe urgency, and almost 50% complaining of stress incontinence. 4 Urge incontinence in particular is more prevalent following the menopause, the prevalence would appear to rise with increasing years of oestrogen deficiency. Oestrogen receptors The effects of the steroid hormone 17h-oestradiol are mediated by ligand activated transcription factors known as oestrogen receptors. These are glycoproteins and share common features with both androgen and progesterone receptors and can be divided into several functional domains. The classic oestrogen receptor (ERa) was first discoveredbyjensenin1958andclonedfromuterinetissue in 1986, 5 although it was not until 1996 that the second oestrogen receptor (ERh) was identified. 6 The precise role of the two different receptors remains to be elucidated although ERa appears to play a major role in the regulation of reproduction whilst ERh has a more minor role. 7 URINARY INCONTINENCE Oestrogens and lower urinary tract symptoms Oestrogens play an important role in the continence mechanism with bladder and urethral function becoming less efficient with age. 8 Elderly women have been found to have a reduced flow rate, increased urinary residuals, higher filling pressures, reduced bladder capacity and lower maximum voiding pressures. Oestrogens may affect continence by increasing urethral resistance, raising the sensory threshold of the bladder, by increasing a adrenoreceptor sensitivity in the urethral smooth muscle 9 or by promoting h-3-adrenoceptormediated relaxation of the detrusor muscle. 10 In addition exogenous oestrogens have been shown to increase the number of intermediate and superficial cells in the vagina of postmenopausal women. 11 These changes have also been demonstrated in the bladder and urethra. 12 Cyclical variations in the levels of both oestrogen and progesterone during the menstrual cycle have been shown to lead to changes in urodynamic variables and lower urinary tract symptoms, with 37% of women noticing a deterioration in symptoms prior to menstruation. 13 Measurement of the urethral pressure profile in nulliparous premenopausal women shows there is an increase in functional urethral length midcycle and early in the luteal phase corresponding to an increase in plasma oestradiol. 14 Furthermore, progestogens have been associated with an increase in irritative bladder symptoms and urinary incontinence in those women taking combined hormone replacement therapy. 15 The incidence of detrusor overactivity in the luteal phase of the menstrual cycle may be associated with raised plasma progesterone following ovulation and progesterone has been shown to antagonize the inhibitory effect of oestradiol on rat detrusor contractions. 16 This may help to explain the increased prevalence of detrusor overactivity found in pregnancy. Department of Urogynaecology, Kings College Hospital, London, UK Correspondence: Dr D. Robinson, Department of Urogynaecology, 3rd Floor Golden Jubilee Wing, Kings College Hospital, London SE5 9RS, UK. D RCOG 2004 BJOG: an International Journal of Obstetrics and Gynaecology Oestrogens in the management of urinary incontinence Oestrogen preparations have been used for many years in the treatment of urinary incontinence although their precise role remains controversial. Many of the studies performed
2 have been uncontrolled observational series examining the use of a wide range of different preparations, doses and routes of administration. The inconsistent use of progestogens to provide endometrial protection is a further confounding factor making interpretation of the results difficult. In order to clarify the situation a meta-analysis from the Hormones and Urogenital Therapy (HUT) Committee has been completed. 17 Of 166 articles identified that were published in English between 1969 and 1992, only six were controlled trials and 17 were uncontrolled series. Metaanalysis found an overall significant effect of oestrogen therapy on subjective improvement in all subjects and for subjects with urodynamic stress incontinence alone. Subjective improvement rates with oestrogen therapy in randomised controlled trials ranged from 64% to 75%, although placebo groups also reported an improvement of 10% to 56%. In uncontrolled series subjective improvement rates were 8% to 89%. A further meta-analysis performed in Italy has analysed the results of randomised controlled clinical trials on the efficacy of oestrogen treatment in postmenopausal women with urinary incontinence. 18 A search of the literature ( ) revealed 72 articles of which only four were considered to meet the meta-analysis criteria. There was a statistically significant difference in subjective outcome between oestrogen and placebo although there was no such difference in objective or urodynamic outcome. The authors conclude that this difference could be relevant although the studies may have lacked objective sensitivity to detect this. The role of oestrogen replacement therapy in the prevention of ischaemic heart disease has recently been assessed in a 4-year randomised trial, the Heart and Estrogen/progestin Replacement Study (HERS), 19 involving 2763 postmenopausal women younger than 80 years with intact uteri and ischaemic heart disease. In the study 55% of women reported at least one episode of urinary incontinence each week, and were randomly assigned to oral conjugated oestrogen plus medroxyprogesterone acetate or placebo daily. Incontinence improved in 26% of women assigned to placebo as compared with 21% receiving HRT, while 27% of the placebo group complained of worsening symptoms compared with 39% in the HRT group (P ¼ 0.001). The incidence of incontinent episodes per week increased an average of 0.7 in the HRT group and decreased by 0.1 in the placebo group (P < 0.001). Overall combined hormone replacement therapy was associated with worsening stress and urge urinary incontinence, although there was no significant difference in daytime frequency, nocturia or number of urinary tract infections. The role of oestrogens for urinary incontinence has recently been subjected to Cochrane review. 20 Overall 28 trials, including 2926 women, were identified. The trials reported used varying combinations of type of oestrogen, OESTROGENS AND THE LOWER URINARY TRACT 11 dose, route of administration and duration of therapy. Subjective impression of cure was higher amongst those treated with oestrogen for all types of incontinence and when considered jointly with improvement there was a statistically higher rate in both urge and stress incontinence when compared with placebo; 57% vs 28% and 43% vs 27%, respectively. In women with urge incontinence the chance of cure or improvement was 25% higher than in those with stress incontinence. Overall the data would suggest that 50% of women taking oestrogen were subjectively cured or improved compared with 25% who were taking placebo. Whilst the effect tended to be more marked in those women complaining of urge incontinence there was no statistically significant effect on frequency, nocturia or urgency. Oestrogens in the management of stress incontinence In addition to the studies included in the HUT metaanalysis several authors have also investigated the role of oestrogen therapy in the management of urodynamic stress incontinence only. Oral oestrogens have been reported to increase the maximum urethral pressures and lead to symptomatic improvement in 65% 70% of women, 21,22 although other work has not confirmed this. 23,24 More recently two placebo-controlled studies have been performed examining the use of oral oestrogens in the treatment of urodynamic stress incontinence in postmenopausal women. Neither conjugated equine oestrogens and medroxyprogesterone 25 or unopposed oestradiol valerate 26 showed a significant difference in either subjective or objective outcomes. Furthermore, a review of eight controlled and 14 uncontrolled prospective trials concluded that oestrogen therapy was not an efficacious treatment for stress incontinence but may be useful for symptoms of urgency and frequency. 27 A recently reported meta-analysis has helped determine the role of oestrogen replacement in women with stress incontinence. 28 Of the papers reviewed 14 were nonrandomised studies, six randomised trials (of which four were placebo controlled) and two meta-analyses. Interestingly there was only a symptomatic or clinical improvement noted in the nonrandomised studies whilst there was no such effect noted in the randomised trials. The authors conclude that currently the evidence would not support the use of oestrogen replacement alone in the management of stress incontinence. Oestrogens in the management of urge incontinence Oestrogens have been used in the treatment of urinary urgency and urge incontinence for many years although there have been few controlled trials to confirm their D RCOG 2004 BJOG: an International Journal of Obstetrics and Gynaecology 111 (Suppl. 1), pp
3 12 D. ROBINSON & L. CARDOZO efficacy. A double-blind placebo-controlled crossover study using oral oestriol in 34 postmenopausal women produced subjective improvement in eight women with mixed incontinence and 12 with urge incontinence. 29 However, a double-blind multicentre study of the use of oestriol (3 mg per day) in postmenopausal women complaining of urgency has failed to confirm these findings, 30 showing both subjective and objective improvement but not significantly better than placebo. The use of sustained release 17h-oestradiol vaginal tablets (Vagifem, Novo Nordisk) has also been examined in postmenopausal women with urgency and urge incontinence or a urodynamic diagnosis of sensory urgency or detrusor overactivity. These vaginal tablets have been shown to be well absorbed from the vagina and to induce maturation of the vaginal epithelium within 14 days. 31 However, following a 6-month course of treatment the only significant difference between active and placebo groups was an improvement in the symptom of urgency in those women with a urodynamic diagnosis of sensory urgency. 32 A further double-blind, randomised, placebo-controlled trial of vaginal 17ha-oestradiol vaginal tablets has shown lower urinary tract symptoms of frequency, urgency, urge and stress incontinence to be significantly improved although there was no objective urodynamic assessment performed. 33 In both of these studies the subjective improvement in symptoms may simply represent local oestrogenic effects reversing urogenital atrophy rather than a direct effect on bladder function. More recently a randomised, parallel group, controlled trial has been reported comparing the oestradiol-releasing vaginal ring (Estring, Pharmacia, Uppsala, Sweden) with oestriol vaginal pessaries in the treatment of postmenopausal women with bothersome lower urinary tract symptoms. 34 Low-dose vaginally administered oestradiol and oestriol were found to be equally efficacious in alleviating lower urinary tract symptoms of urge incontinence (58% vs 58%), stress incontinence (53% vs 59%) and nocturia (51% vs 54%) although the vaginal ring was found to have greater patient acceptability. To try and clarify the role of oestrogen therapy in the management of women with urge incontinence a metaanalysis of the use of oestrogen in women with symptoms of overactive bladder has been reported by the HUT Committee. 35 In a review of 11 randomised placebocontrolled trials including 430 women oestrogen was foundtobesuperiortoplacebo when considering symptoms of urge incontinence, frequency and nocturia, although vaginal oestrogen administration was found to be superior for symptoms of urgency. In those taking oestrogens there was also a significant increase in first sensation and bladder capacity as compared with placebo. In conclusion oestrogen therapy was found to improve lower urinary tract symptoms as well as urodynamic variables and local administration was superior to systemic. RECURRENT URINARY TRACT INFECTIONS Oestrogens in the management of recurrent urinary tract infection Oestrogen therapy has been shown to increase vaginal ph and reverse the microbiological changes that occur in the vagina following the menopause. 36 Initial small uncontrolled studies using oral or vaginal oestrogens in the treatment of recurrent urinary tract infection appeared to give promising results, 37,38 although unfortunately this has not been supported by larger randomised trials. Several studies have been performed examining the use of oral and vaginal oestrogens although these have had mixed results. Kjaergaard and colleagues 39 compared vaginal oestriol tablets with placebo in 21 postmenopausal women over a 5-month period and found no significant difference between the two groups. However, a subsequent randomised, double-blind placebo-controlled study assessing the use of oestriol vaginal cream in 93 postmenopausal women during an 8-month period did reveal a significant effect. 40 Kirkengen randomised 40 postmenopausal women to receive either placebo or oral oestriol and found that although initially both groups had a significantly decreased incidence of recurrent infections, after 12 weeks oestriol was shown to be significantly more effective. 41 These findings, however, were not confirmed subsequently in a trial of 72 postmenopausal women with recurrent urinary tract infections randomised to oral oestriol or placebo. Following a 6-month treatment period and a further 6-month follow up oestriol was found to be no more effective than placebo. 42 More recently a randomised, open, parallel-group study assessing the use of an oestradiol-releasing silicone vaginal ring (Estring; Pharmacia) in postmenopausal women with recurrent infections has been performed which showed the cumulative likelihood of remaining infection free was 45% in the active group and 20% in the placebo group. 43 Estring was also shown to decrease the number of recurrences per year and to prolong the interval between infection episodes. CONCLUSION Oestrogens are known to have an important physiological effect on the female lower genital tract throughout adult life leading to symptomatic, histological and functional changes. The use of oestrogen replacement therapy has been examined in the management of lower urinary tract symptoms although only recently has it been subjected to randomised placebo-controlled trials and metaanalysis. Oestrogen therapy alone has been shown to have little effect in the management of urodynamic stress incontinence, although when used in combination with an D RCOG 2004 BJOG: an International Journal of Obstetrics and Gynaecology 111 (Suppl. 1), pp
4 OESTROGENS AND THE LOWER URINARY TRACT 13 a-adrenergic agonist may lead to an improvement in urinary leakage. When considering the irritative symptoms of urinary urgency, frequency and urge incontinence oestrogen therapy may be of benefit, although this may simply represent reversal of urogenital atrophy rather than a direct effect on the lower urinary tract. The role of oestrogen replacement therapy in the management of women with recurrent lower urinary tract infection remains to be determined although there is now some evidence that vaginal administration may be efficacious. References 1. Iosif S, Batra S, Ek A, Astedt B. Oestrogens receptors in the human female lower urinary tract. Am J Obstet Gynaecol 1981;141: Batra SC, Iosif LS. Progesterone receptors in the female urinary tract. J Urol 1987;138: Iosif C, Bekassy Z. Prevalence of genitourinary symptoms in the late menopause. Acta Obstet Gynaecol Scand 1984;63: Cardozo LD, Tapp A, Versi E, Samsioe G, Bonne Erickson P, editors. The lower urinary tract in peri- and postmenopausal women. In: The Urogenital Deficiency Syndrome. Bagsverd, Denmark: Novo Industri AS. 1987: Green S, Walter P, Kumar V, et al. Human oestrogen receptor cdna sequence, expression and homology to v-erba. Nature 1986;320: Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel oestrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93: Warner M, Nilsson S, Gustafsson JA. The oestrogen receptor family. Curr Opin Obstet Gynaecol 1999;11: Rud T, Anderson KE, Asmussen M, et al. Factors maintaining the urethral pressure in women. Invest Urol 1980;17: Kinn AC, Lindskog M. Oestrogens and phenylpropanolamine in combination for stress incontinence. Urology 1988;32: Matsubara S, Okada H, Shirakawa Gotoh A, Kuno T, Kamidono S. Oestrogen levels influence beta-3-adrenceptor-mediated relaxation of the female rat detrusor muscle. Urology 2002;59: Smith PJB. The effect of oestrogens on bladder function in the female. In: Campbell S, editor. The Management of the Menopause and Postmenopausal Years. Carnforth: MTP, 1976: Samsioe G, Jansson I, Mellstrom D, Svandborg A. Occurance, nature and treatment of urinary incontinence in a 70 year old female population. Maturitas 1985;7: Hextall A, Bidmead J, Cardozo L, Hooper R. Hormonal influences on the human female lower urinary tract: a prospective evaluation of the effects of the menstrual cycle on symptomatology and the results of urodynamic investigation. Neurourol Urodyn 1999;18: Van Geelen JM, Doesburg WH, Thomas CMG. Urodynamic studies in the normal menstrual cycle: the relationship between hormonal changes during the menstrual cycle and the urethral pressure profile. Am J Obstet Gynaecol 1981;141: Benness C, Gangar K, Cardozo LD, Cutner A. Do progestogens exacerbate urinary incontinence in women on HRT? Neurourol Urodyn 1991;10: Elliot RA, Castleden CM. Effect of progestagens and oestrogens on the contractile response of rat detrusor muscle to electrical field stimulation. Clin Sci 1994;87: Fantl JA, Cardozo LD, McClish DK, and the Hormones and Urogenital Therapy Committee. Oestrogen therapy in the management of incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynaecol 1994;83: Zullo MA, Oliva C, Falconi G, Paparella P, Mancuso S. Efficacy of oestrogen therapy in urinary incontinence. A meta-analytic study. Minerva Ginecol 1998;50: Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Synder T. Postmenopausal hormones and incontinence: the Heart and Estrogen/ progestin Replacement Study. Obstet Gynaecol 2001;97: Moeher B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women [Cochrane review]. In: The Cochrane Library, Issue 3. Oxford: Update Software, Caine M, Raz S. The role of female hormones in stress incontinence. In: Proceedings of the 16th Congress of the International Society of Urology. Amsterdam, the Netherlands. 22. Rud T. The effects of oestrogens and gestagens on the urethral pressure profile in urinary continent and stress incontinent women. Acta Obstet Gynaecol Scand 1980;59: Wilson PD, Faragher B, Butler B, Bullock D, Robinson EL, Brown ADG. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol 1987;94: Walter S, Wolf H, Barlebo H, Jansen H. Urinary incontinence in postmenopausal women treated with oestrogens: a double-blind clinical trial. J Urol 1978;33: Fantl JA, Bump RC, Robinson D, et al. Efficacy of oestrogen supplementation in the treatment of urinary incontinence. Obstet Gynaecol 1996;88: Jackson S, Shepherd A, Brookes S, Abrams P. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind, placebo controlled trial. Br J Obstet Gynaecol 1999;106: Sultana CJ, Walters MD. Oestrogen and urinary incontinence in women. Maturitas 1995;20: Ahmed Al-Badr Ross S, Soroka D, Drutz HP. What is the available evidence for hormone replacement therapy in women with stress urinary incontinence? J Obstet Gynaecol Can 2003;25: Samsicoe G, Jansson I, Mellstrom D, Svanberg A. Urinary incontinence in 75 year old women. Effects of oestriol. Acta Obstet Gynaecol Scand 1985;93: Cardozo LD, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas 1993;18: Nilsson K, Heimer G. Low dose oestradiol in the treatment of urogenital oestrogen defiiciency a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15: Benness C, Wise BG, Cutner A, Cardozo LD. Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women. Int Urogynaecol J 1992;3: Eriksen PS, Rasmussen H. Low dose 17h-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynaecol Reprod Biol 1992;44: Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. Br J Obstet Gynaecol 2000;107: Cardozo L, Lose G, McClish D, Versi E. Estrogen treatment for symptoms of an overactive bladder, results of a meta analysis. Int J Urogynaecol 2001;12:V. 36. Brandberg A, Mellstrom D, Samsioe G. Low dose oral oestriol treatment in elderly women with urogenital infections. Acta Obstet Gynaecol Scand 1987;140: Parsons CL, Schmidt JD. Control of recurrent urinary tract infections in postmenopausal women. J Urol 1982;128: Privette M, Cade R, Peterson J, et al. Prevention of recurrent urinary tract infections in postmenopausal women. Nephron 1988;50: Kjaergaard B, Walter S, Knudsen A, et al. Treatment with low dose vaginal oestradiol in postmenopausal women. A double blind controlled trial. Ugeskr Laeger 1990;152: Raz R, Stamm WE. A controlled trial of intravaginal oestriol in D RCOG 2004 BJOG: an International Journal of Obstetrics and Gynaecology 111 (Suppl. 1), pp
5 14 D. ROBINSON & L. CARDOZO postmenopausal women with recurrent urinary tract infections. New Eng J Med 1993;329: Kirkengen AL, Anderson P, Gjersoe E, et al. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scan J Prim Health Care 1992;10: Cardozo LD, Benness C, Abbott D. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. Br J Obstet Gynaecol 1998;105: Eriksen B. A randomised, open, parallel-group study on the preventitive effect of an oestradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynaecol 1999;180: D RCOG 2004 BJOG: an International Journal of Obstetrics and Gynaecology 111 (Suppl. 1), pp
A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women
MENOPAUSE A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women Cheng-Yu Long, M.D., a,b Cheng-Min Liu, M.D.,
More informationThe relationship between urinary symptom questionnaires and urodynamic diagnoses: an analysis of two methods of questionnaire administration
BJOG: an International Journal of Obstetrics and Gynaecology May 2004, Vol. 111, pp. 468 474 DOI: 1 0. 1111/j.1471-0528.2004.00126.x The relationship between urinary symptom questionnaires and urodynamic
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationThe development of a questionnaire to measure the severity of symptoms and the quality of life before and after surgery for stress incontinence
BJOG: an International Journal of Obstetrics and Gynaecology November 2003, Vol. 110, pp. 983 988 The development of a questionnaire to measure the severity of symptoms and the quality of life before and
More informationHormonal replacement therapy and urinary problems as evaluated by ultrasound and color Doppler
Ultrasound Obstet Gynecol 999;:4 44 Hormonal replacement therapy and urinary problems as evaluated by ultrasound and color Doppler C. Battaglia, M. Salvatori, S. Giulini, M. R. Primavera, A. Gallinelli
More informationYear: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy
Year: 2013 - Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy By: Dr David W Sturdee, Immediate past President International Menopause Society and Hon Consultant Gynaecologist, Solihull
More informationOestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status
BJU International (2000), 86, 32±38 Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status P.J. BLAKEMAN, P. HILTON and J.N. BULMER Departments
More informationMenopause, the cessation
Estrogen and Its Effect on Vaginal Atrophy in Post-Menopausal Women Charlotte Kelley Menopause, the cessation of menstruation for 6 to 12 months, is a natural progression of life for women (O Toole, 2003).
More informationManagement of Urinary Incontinence in Older Women. Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital
Management of Urinary Incontinence in Older Women Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital Epidemiology Causes Investigation Treatment Conclusion Elderly Women High prevalence
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationModule 3 Causes Of Urinary Incontinence
Causes Of Urinary Incontinence V4: Last Reviewed September 2017 Learning Outcomes Appreciate the numerous requirements and skills necessary for the person to achieve and maintain urinary continence Discuss
More informationResearch. Estrogen receptors have been identified
Research UROGYNECOLOGY Postmenopausal hormone therapy and incident urinary incontinence in middle-aged women Mary K. Townsend, ScD; Gary C. Curhan, MD, ScD; Neil M. Resnick, MD; Francine Grodstein, ScD
More informationOveractive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women.
Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women. Teleman, Pia; Lidfeldt, Jonas; Nerbrand, Christina; Samsioe, Göran; Mattiasson, Anders Published in:
More informationEffects of Local EstrogenTherapy on Recurrent UrinaryTract Infections inyoung Females under Oral Contraceptives
European Urology European Urology 47 (2005) 243 249 Effects of Local EstrogenTherapy on Recurrent UrinaryTract Infections inyoung Females under Oral Contraceptives Germar-M. Pinggera a, *, Gudrun Feuchtner
More informationNORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR GENERAL PRACTICE
JUNE 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Venous Leg Ulcers
More informationApril Clinical Focus Topic URINARY FREQUENCY
April Clinical Focus Topic URINARY FREQUENCY This month I am focusing on a topic that may seem a little boring. But I would like to look at it from a less common perspective.urinary Frequency and its relationship
More informationEffects of Combined Pelvic Floor Muscle Exercises in Patient with Urinary Incontinence
MACROJOURNALS The Journal of MacroTrends in Health and Medicine Effects of Combined Pelvic Floor Muscle Exercises in Patient with Urinary Incontinence Vjollca Ndreu*, Fatjona Kamberi*, Enkeleda Sinaj*,
More informationBJUI. Validity and reliability of the patient s perception of intensity of urgency scale in overactive bladder
; 2010 Lower Urinary Tract PATIENT S PERCEPTION OF INTENSITY OF URGENCY SCALE IN OAB CARTWRIGHT ET AL. BJUI Validity and reliability of the patient s perception of intensity of urgency scale in overactive
More informationThe urethral support system during pregnancy and after childbirth Wijma, Jacobus
University of Groningen The urethral support system during pregnancy and after childbirth Wijma, Jacobus IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationThe Management of Female Urinary Incontinence. Part 1: Aetiology and Investigations
The Management of Female Urinary Incontinence Part 1: Aetiology and Investigations Dr Oseka Onuma Gynaecologist and Pelvic Reconstructive Surgeon 4 Robe Terrace Medindie SA 5081 Urinary incontinence has
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationInternational Urogynecological Association (IUGA) Observership Grant. Final Report
International Urogynecological Association (IUGA) 2009-10 Observership Grant Final Report Observership Grant Recipient: Renato Silva Martins 5 th Year Obstetrics and Gynaecology Resident at Coimbra s University
More informationDuloxetine in women awaiting surgery
DOI: 1.1111/j.1471-528.6.879.x www.blackwellpublishing.com/bjog Review article H Drutz Ontario Power Generation Building, Toronto, Ontario, Canada Correspondence: Prof. Dr H Drutz, Mount Sinai Hospital,
More informationThe diagnostic strength of the 24-h pad test for self-reported symptoms of urinary incontinence in pregnancy and after childbirth
Int Urogynecol J (8) 19:525 53 DOI.7/s192-7-472-z ORIGINAL ARTICLE The diagnostic strength of the 24-h pad test for self-reported symptoms of urinary incontinence in pregnancy and after childbirth Jacobus
More informationMr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.
Mr. GIT KAH ANN Pakar Klinikal Urologi Hospital Kuala Lumpur drgitka@yahoo.com 25 Jan 2007 HIGHLIGHTS Introduction ICS Definition Making a Diagnosis Voiding Chart Investigation Urodynamics Ancillary Investigations
More informationJohn Laughlin 4 th year Cardiff University Medical Student
John Laughlin 4 th year Cardiff University Medical Student Prolapse/incontinence You need to know: Pelvic floor anatomy in relation to uterovaginal support and continence The classification of uterovaginal
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationProlapse and Urogynae Incontinence. Lucy Tiffin and Hannah Wheldon-Holmes
Prolapse and Urogynae Incontinence Lucy Tiffin and Hannah Wheldon-Holmes 66 year old woman with incontinence PC: 7 year Hx of urgency, frequency, nocturia (incl. incontinence at night), and stress incontinence
More informationEstrogen (conjugated estrogens & ethinyl estradiol) Addition to the List
Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List Note: Commonly prescribed medication. Literature question Is estrogen effective and safe? Are conjugated estrogens effective and
More informationManagement of Female Stress Incontinence
Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss
More informationUse of vaginal estrogen in Danish women: a nationwide cross-sectional study
AOGS ORIGINAL RESEARCH ARTICLE Use of vaginal estrogen in Danish women: a nationwide cross-sectional study AMANI MEAIDI 1,, IRINA GOUKASIAN & OEJVIND LIDEGAARD 1 1 Department of Gynecology, Rigshospitalet
More informationContent. Terminology Anatomy Aetiology Presentation Classification Management
Prolapse Content Terminology Anatomy Aetiology Presentation Classification Management Terminology Prolapse Descent of pelvic organs into the vagina Cystocele ant. vaginal wall involving bladder Uterine
More informationArvind Vashisht MD MRCOG
Arvind Vashisht MD MRCOG Qualifications 1989-1992 St Catharine s College, Cambridge University March 01 June 92 M.A. Hons B.A. Hons 1992-1995 The London Hospital Medical College, London June 95 M.B.B.S.
More informationOveractive Bladder: Diagnosis and Approaches to Treatment
Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds
More informationBen Herbert Alex Wojtowicz
Ben Herbert Alex Wojtowicz 54 year old female presenting with: Dragging sensation Urinary incontinence Some faecal incontinence HPC Since May 14 had noticed a mass protruding from the vagina when going
More informationTable 1. International Consultation on Incontinence recommendations for frail older adults
Table 1. International Consultation on Incontinence recommendations for frail older adults Clinicians need to assess and manage co-existing co morbid conditions which are known to have an impact on continence
More informationTreatment Outcomes of Tension-free Vaginal Tape Insertion
Are the Treatment Outcomes of Tension-free Vaginal Tape Insertion the Same for Patients with Stress Urinary Incontinence with or without Intrinsic Sphincter Deficiency? A Retrospective Study in Hong Kong
More informationPRE-OPERATIVE URODYNAMIC
PRE-OPERATIVE URODYNAMIC STUDIES: IS THERE VALUE IN PREDICTING POST-OPERATIVE STRESS URINARY INCONTINENCE IN WOMEN UNDERGOING PROLAPSE SURGERY? Dr K Janse van Rensburg Dr JA van Rensburg INTRODUCTION POP
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationThe Effects Of Different Sex Hormones On Female Rabbit Urodynamics: An Experimental Study
ISPUB.COM The Internet Journal of Urology Volume 2 Number 2 The Effects Of Different Sex Hormones On Female Rabbit Urodynamics: An Experimental Study S Celayir, Z Ilce Citation S Celayir, Z Ilce. The Effects
More information2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK
2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail
More informationUrinary and faecal incontinence following delayed primary repair of obstetric genital fistula
BJOG: an International Journal of Obstetrics and Gynaecology July 2002, Vol. 109, pp. 828 832 Urinary and faecal incontinence following delayed primary repair of obstetric genital fistula Christine Murray,
More informationURINARY INCONTINENCE AMONG OBESE WOMEN: A CROSS- SECTIONAL STUDY
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Aisha et al. SJIF Impact Factor 6.647 Volume 6, Issue 9, 1384-1391 Research Article ISSN 2278 4357 URINARY INCONTINENCE AMONG OBESE WOMEN: A CROSS-
More informationIncontinence: The silent scourge of the young and old. The International Continence Society has. In this article:
Focus on CME at the University of Toronto Incontinence: The silent scourge of the young and old By Sender Herschorn, BSc, MDCM, FRCSC In this article: 1. What is the workup for urinary incontinence? 2.
More informationUrethral pressure measurement in stress incontinence: does it help?
Int Urol Nephrol (2009) 41:491 495 DOI 10.1007/s11255-008-9506-9 UROLOGY - ORIGINAL PAPER Urethral pressure measurement in stress incontinence: does it help? Bassem S. Wadie Æ Ahmed S. El-Hefnawy Received:
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationUrodynamics in women. Aims of Urodynamics in women. Why do Urodynamics?
Urodynamics in women Chendrimada Madhu MD, MA, MRCOG Subspecialty Trainee in Urogynaecology Southmead Hospital 2013 Aims of Urodynamics in women n Confirmation of incontinence and its cause n Definition
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationThe new International Continence Society
ROLE OF CYSTOMETRY IN EVALUATING PATIENTS WITH OVERACTIVE BLADDER ADAM J. FLISSER AND JERRY G. BLAIVAS ABSTRACT Overactive bladder (OAB) can be caused by a variety of conditions. We believe that cystometrography
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationGlossary of terms Urinary Incontinence
Patient Information English Glossary of terms Urinary Incontinence Anaesthesia (general, spinal, or local) Before a procedure you will get medication to make sure that you don t feel pain. Under general
More informationINCONTINENCE. Continence and Pelvic Floor Rehabilitation TYPES OF INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE 11/08/2015
INCONTINENCE Continence and Pelvic Floor Rehabilitation Dr Irmina Nahon PhD Pelvic Floor Physiotherapist www.nahonpfed.com.au Defined as the accidental and inappropriate passage of urine or faeces (ICI
More informationOriginal Article INTRODUCTION
Original Article A comparative study of vaginal estrogen cream and sustained-release estradiol vaginal tablet (Vagifem) in the treatment of atrophic vaginitis in Isfahan, Iran in 2010-2012 Pardis Hosseinzadeh,
More informationTelford and Wrekin Clinical Commissioning Group
Telford and Wrekin Clinical Commissioning Group Agenda Item 9.2 CLINICAL COMMISSIONING GROUP GOVERNANCE BOARD EXECUTIVE SUMMARY DATE: 9 th April 2013 TITLE OF PAPER: Continence pathway and Referral letter
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationFunctional anatomy of the female pelvic floor and lower urinary tract Stefano Floris, MD, PhD Department of Obstetrics and Gynaecology
Functional anatomy of the female pelvic floor and lower urinary tract Stefano Floris, MD, PhD Department of Obstetrics and Gynaecology Ospedale San Giovanni di Dio, Gorizia, Italy ANATOMY URINARY CONTINENCE
More informationInnovations in the Management of Dyspareunia
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCompassionate and effective management
IMPACT OF STRESS URINARY INCONTINENCE ON QUALITY OF LIFE * Paul Abrams, MD, FRCS ABSTRACT Evaluating the impact of stress urinary incontinence (SUI) on quality of life (QOL) is of paramount importance,
More informationPatient Information. Basic Information on Overactive Bladder Symptoms. pubic bone. urethra. scrotum. bladder. vaginal canal
Patient Information English Basic Information on Overactive Bladder Symptoms The underlined terms are listed in the glossary. What is the bladder? pubic bone bladder seminal vesicles prostate rectum The
More informationKathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA
Kathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA Disclosures Advisory Board and/or Speaker Allergan Medtronic Astellas AUA Guidelines
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationIn evaluating a patient with lower urinary tract symptoms (LUTS), urologists
CLINICAL MANAGEMENT OF INTERSTITIAL CYSTITIS Interstitial Cystitis and Lower Urinary Tract Symptoms in Males and Females The Combined Role of Potassium and Epithelial Dysfunction C. Lowell Parsons, MD
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationORIGINAL INVESTIGATION. Risk Factors for Urinary Tract Infections
ORIGINAL INVESTIGATION Risk Factors for Urinary Tract Infections in Postmenopausal Women Kent K. Hu, MD; Edward J. Boyko, MD, MPH; Delia Scholes, PhD; Esther Normand, RRT; Chi-Ling Chen, PhD; Jane Grafton;
More informationA Simplified Urinary Incontinence Score for the Evaluation of Treatment Outcomes
Neurourology and Urodynamics 19:127 135 (2000) A Simplified Urinary Incontinence Score for the Evaluation of Treatment Outcomes Asnat Groutz, Jerry G. Blaivas,* and Jarrod E. Rosenthal Weill Medical College,
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationVarious Types. Ralph Boling, DO, FACOG
Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with
More informationMenopause & HRT. Rosie & Alex. Image:
Menopause & HRT Rosie & Alex Image: http://www.keepcalm-o-matic.co.uk/ Menopause The permanent cessation of menstruation for 12 months When does it happen? Average age 51 Image: Nature Medicine - 12, 612-613
More informationSurgical management of stress urinary incontinence in Scotland and Wales: A questionnaire study
International Journal of Surgery (2007) 5, 162e166 www.theijs.com Surgical management of stress urinary incontinence in Scotland and Wales: A questionnaire study Min Yu Lim a, *, Mahesh Perera b, Ian Ramsay
More informationDr. Mojibian. Menopause
Dr. Mojibian Menopause I. Introduction - The term menopause is derived from Greek Meno (months) and pause (cessation). The word means cessation of menstruation. - Cliamacteric which is by dictionary definition
More informationUrinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
More informationMenopause & HRT. Matt McKenna Elliot Davis
Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea
More informationLET S START WITH (AND REMEMBER WE ARE TALKING ABOUT LOCAL E2) THERAPUTIC AGENTS: ARE THEY SAFE? Systemic HT/ET. Ospemifene. Local Estrogen Therapy
THERAPUTIC AGENTS: ARE THEY SAFE? Steven R. Goldstein, M.D. Professor of Obstetrics & Gynecology New York University School of Medicine Director of Gynecologic Ultrasound Co-Director of Bone Densitometry
More informationFemale Pelvic Medicine & Reconstructive Surgery
Female Pelvic Medicine & Reconstructive Surgery APPLICATION FOR NEW FELLOWSHIP Name of Institution: McGill University Location: Royal Victoria Hospital (Glen Site), St Mary s Hospital Centre Type of Fellowship:
More informationDuloxetine, a Serotonin and Noradrenaline Reuptake Inhibitor (SNRI) for the Treatment of Stress Urinary Incontinence: A Systematic Review
european urology 51 (2007) 67 74 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Female Urology Incontinence Duloxetine, a Serotonin and Noradrenaline Reuptake Inhibitor
More informationPREVENTING URINARY INCONTINENCE through PELVIC FLOOR REHABILITATION in DISABLED ELDERLY
PREVENTING URINARY INCONTINENCE through PELVIC FLOOR REHABILITATION in DISABLED ELDERLY Paolo DI BENEDETTO Lecturer, Tor Vergata University, Rome, Italy Former Director of Rehabilitation Department Institute
More informationFACTORS AFFECTING VOIDING FUNCTION IN UROGYNECOLOGY PATIENTS
ORIGINAL ARTICLE FACTORS AFFECTING VOIDING FUNCTION IN UROGYNECOLOGY PATIENTS Ling-Hong Tseng*, Ching-Chung Liang, Pei-Kwei Tsay 1, Alex C. Wang, Tsia-Shu Lo, Yi-Hao Lin Department of Obstetrics and Gynecology,
More informationHormone Replacement Therapy (HRT) Benefits & Risks - The Facts
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More informationCURRICULUM VITAE LINDA CARDOZO
CURRICULUM VITAE LINDA CARDOZO 2004 2 Name: Linda Dolores CARDOZO Date of Birth: 15th September 1950 Place of Birth: London, England Marital Status: Married, 3 children (born 27.2.89 & 27.7.90) Medical
More informationVaginal atrophy is a common condition
original article Oman Medical Journal [2017], Vol. 32, No. 1: 15 19 Treatment of Vaginal Atrophy with Vaginal Estrogen Cream in Menopausal Indian Women Maitri Shah 1 *, Zalak Karena 1, Sangita V. Patel
More informationManaging Female Urinary Incontinence Within Primary Care
Managing Female Urinary Incontinence Within Primary Care Angela Patterson Lead Clinical Nurse Specialist in Bladder and Bowel Dysfunction. South Eastern HSCT Background More than 14 million in the UK affected
More informationInterventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566
Single-incision short sling mesh insertion for stress urinary incontinence in women Interventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566 Your responsibility This guidance
More informationOestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women (Review)
Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women (Review) Ismail SI, Bain C, Hagen S This is a reprint of a Cochrane review, prepared and maintained by The Cochrane
More informationJMSCR Vol 06 Issue 06 Page June 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i6.07 Study of Cervical Cytology (Pap
More informationUP DATE MANAGEMENT OF URINARY INCONTINENCE IN ADULT
UP DATE MANAGEMENT OF URINARY INCONTINENCE IN ADULT Yunizaf, MD Division of Urogynecology Department of Obstetrics and Gynecology School of Medicine, University of Indonesia/ Dr. Cipto Mangunkusumo Hospital
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationPublic Assessment Report Scientific discussion. Gelistrol (estriol) SE/H/906/01/DC
Public Assessment Report Scientific discussion Gelistrol (estriol) SE/H/906/01/DC This module reflects the scientific discussion for the approval of Gelistrol. The procedure was finalised at 2010-07-28.
More informationBioidentical Hormone Preparations - History of Development
Bioidentical Hormone Preparations - History of Development The use of the terminology BIOIDENTICAL HORMONE therapy has aroused much controversy and heated debate over the past 20 years, often with much
More informationBothersome lower urinary symptoms during pregnancy: a preliminary study using the International Consultation on Incontinence Questionnaire
Bothersome lower urinary symptoms during pregnancy: a preliminary study using the International Consultation on Incontinence Questionnaire *Adaji SE, Shittu OS, Bature SB, Nasir S, Olatunji O Urogynaecology
More informationCommunity Gynaecology. Top Tips for GPs
Community Gynaecology Top Tips for GPs Top Tips for GPs Case Scenarios- common referral themes 6 topics What you can do in Primary Care to avoid or before referral. What we don t need to see Triage ensures
More informationGary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC
Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC 9420 Key West Ave, Suite 420, Rockville, MD 20850 2730 University Blvd, West, Suite 516, Wheaton,
More informationResearch Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms in Postmenopausal Women
Cronicon OPEN ACCESS PHARMACEUTICAL SCIENCE Research Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms Bungau S 1, Tit DM 1 *, Fodor K 1
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationRecurrent urinary tract infections in women with symptoms of pelvic floor dysfunction
Int Urogynecol J (2009) 20:837 842 DOI 10.1007/s00192-009-0856-3 ORIGINAL ARTICLE Recurrent urinary tract infections in women with symptoms of pelvic floor dysfunction Bernard T. Haylen & Joseph Lee &
More informationEffect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder
www.kjurology.org DOI:10.4111/kju.2011.52.6.396 Voiding Dysfunction Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder Young Kook Han, Won Ki Lee, Seong Ho Lee, Dae
More information